Monogenic forms of lipodystrophic syndromes: diagnosis, detection, and practical management considerations from clinical cases

References

• Hussain I, Garg A. Lipodystrophy syndromes. Endocrinol Metab Clin North Am 2016;45:783–97
   PubMed Web of Science ®Google Scholar
• Vatier C, Bidault G, Briand N, et al. What the genetics of lipodystrophy can teach us about insulin resistance and diabetes. Curr Diab Rep 2013;13:757–67
   PubMed Web of Science ®Google Scholar
• Melvin A, O’Rahilly S, Savage DB. Genetic syndromes of severe insulin resistance. Curr Opin Genet Dev 2018;50:60–7
   PubMed Web of Science ®Google Scholar
• Brown RJ, Araujo-Vilar D, Cheung PT, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab 2016;101:4500–11
   PubMed Web of Science ®Google Scholar
• Agarwal AK, Arioglu E, De Almeida S, et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet 2002;31:21–3
   PubMed Web of Science ®Google Scholar
• Magré J, Delépine M, Khallouf E, et al. Identification of the gene altered in Berardinelli-Seip congential lipodystrophy on chromosome 11q13. Nat Genet 2001;28:365–70
   PubMed Web of Science ®Google Scholar
• Nolis T. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. J Hum Genet 2014;59:16–23
   PubMed Web of Science ®Google Scholar
• Caron-Debarle M, Lagathu C, Boccara F, et al. HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol Med 2010;16:218–29
   PubMed Web of Science ®Google Scholar
• Teboul-Coré S, Rey-Jouvin C, Miguel A, et al. Bone imaging findings in genetic and acquired lipodystrophic syndromes: an imaging study of 24 cases. Skeletal Radiol 2016;45:1495–506
   PubMed Web of Science ®Google Scholar
• Girerd X, Hanon O, Anagnostopoulos K, et al. Assessment of antihypertensive compliance using a self-administered questionnaire: development and use in a hypertension clinic. Presse Med 2001;30:1044–8 [in French]
   PubMed Web of Science ®Google Scholar
• Atkinson MJ, Kumar R, Cappelleri JC, et al. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health 2005;8(Suppl 1):S29–S24.12
   Google Scholar
• Magré J, Delépine M, Van Maldergem L, et al. Prevalence of mutations in AGPAT2 among human lipodystrophies. Diabetes 2003;52:1573–8
   PubMed Web of Science ®Google Scholar
• Beltrand J, Beregszaszi M, Chevenne D, et al. Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy. Pediatrics 2007;120:e291–6
   Google Scholar
• Beltrand J, Lahlou N, Le Charpentier T, et al. Resistance to leptin-replacement therapy in Berardinelli-Seip congenital lipodystrophy: an immunological origin. Eur J Endocrinol 2010;162:1083–91
   PubMed Web of Science ®Google Scholar
• Vigouroux C, Magre J, Vantyghem MC, et al. Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy. Diabetes 2000;49:1958–62
   PubMed Web of Science ®Google Scholar
• Van Maldergem L, Magre J, Khallouf TE, et al. Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. J Med Genet 2002;39:722–33
   PubMed Web of Science ®Google Scholar
• Simha V, Garg A. Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. J Clin Endocrinol Metab 2003;88:5433–7
   PubMed Web of Science ®Google Scholar
• Agarwal AK, Simha V, Oral EA, et al. Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J Clin Endocrinol Metab 2003;88:4840–7
   PubMed Web of Science ®Google Scholar
• Lima JG, Nobrega LHC, Lima NN, et al. Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy. PLoS One 2018;13:e0199052
   PubMed Web of Science ®Google Scholar
• Papendieck L, Araujo MB. Clinical outcome in a series of pediatric patients with congenital generalized lipodystrophies treated with dietary therapy. J Pediatr Endocrinol Metab 2018;31:77–83
   PubMed Web of Science ®Google Scholar
• Jéru I, Vatier C, Araujo-Vilar D, et al. Clinical utility gene card for: congenital generalized lipodystrophy. Eur J Hum Genet 2016;24:1649
   Web of Science ®Google Scholar
• Shimomura I, Hammer RE, Ikemoto S, et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999;401:73–6
   PubMed Web of Science ®Google Scholar
• Colombo C, Cutson JJ, Yamauchi T, et al. Transplantation of adipose tissue lacking leptin is unable to reverse the metabolic abnormalities associated with lipoatrophy. Diabetes 2002;51:2727–33
   PubMed Web of Science ®Google Scholar
• Javor ED, Cochran EK, Musso C, et al. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 2005;54:1994–2002
   PubMed Web of Science ®Google Scholar
• Chong AY, Lupsa BC, Cochran EK, et al. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 2010;53:27–35
   PubMed Web of Science ®Google Scholar
• Diker-Cohen T, Cochran E, Gorden P, et al. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. J Clin Endocrinol Metab 2015;100:1802–10
   PubMed Web of Science ®Google Scholar
• Vatier C, Fetita S, Boudou P, et al. One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes. Diabetes Obes Metab 2016;18:693–7
   PubMed Web of Science ®Google Scholar
• Brown RJ, Chan JL, Jaffe ES, et al. Lymphoma in acquired generalized lipodystrophy. Leuk Lymphoma 2016;57:45–50
   PubMed Web of Science ®Google Scholar
• de Azevedo Medeiros LB, Cândido Dantas VK, Craveiro Sarmento AS, et al. High prevalence of Berardinelli-Seip congenital lipodystrophy in Rio Grande do Norte State, Northeast Brazil. Diabetol Metab Syndr 2017;9:80
   PubMedGoogle Scholar
• Mora PF, Ramirez LC, Lender D, et al. Insulin requirements in lipodystrophic diabetes. Diabet Med 1993;10:863–5
   PubMed Web of Science ®Google Scholar
• Lee IH, Chen HL, Jeng YM, et al. Congenital generalized lipodystrophy in a 4-month-old infant. J Formos Med Assoc 2001;100:623–7
   PubMed Web of Science ®Google Scholar
• Montenegro RM Jr, Montenegro AP, Fernandes MI, et al. Triglyceride-induced diabetes mellitus in congenital generalized lipodystrophy. J Pediatr Endocrinol Metab 2002;15:441–7
   Google Scholar
• Vantyghem MC, Balavoine AS, Douillard C, et al. How to diagnose a lipodystrophy syndrome. Ann Endocrinol (Paris) 2012;73:170–89
   PubMed Web of Science ®Google Scholar
• Vigouroux C, Guénantin A-C, Vatier C, et al. Lipodystrophic syndromes due to LMNA mutations: recent developments on biomolecular aspects, pathophysiological hypotheses and therapeutic perspectives. Nucleus 2018;9:235–48
   Google Scholar
• Vantyghem MC, Vincent-Desplanques D, Defrance-Faivre F, et al. Fertility and obstetrical complications in women with LMNA-related familial partial lipodystrophy. J Clin Endocrinol Metab 2008;93:2223–9
   PubMed Web of Science ®Google Scholar
• Araújo-Vilar D, Victoria B, González-Méndez B, et al. Histological and molecular features of lipomatous and nonlipomatous adipose tissue in familial partial lipodystrophy caused by LMNA mutations. Clin Endocrinol (Oxf) 2012;76:816–24
   Google Scholar
• Guillín-Amarelle C, Fernández-Pombo A, Sánchez-Iglesias S, et al. Lipodystrophic laminopathies: diagnostic clues. Nucleus 2018;9:249–60
   Google Scholar
• Fardet L, Kassar A, Cabane J, et al. Corticosteroid-induced adverse events in adults: frequency, screening and prevention. Drug Saf 2007;30:861–81
   PubMed Web of Science ®Google Scholar
• Domingo P, Cabeza Mdel C, Torres F, et al. Association of thymidylate synthase polymorphisms with acute pancreatitis and/or peripheral neuropathy in HIV-infected patients on stavudine-based therapy. PLoS One 2013;8:e57347
   PubMed Web of Science ®Google Scholar
• Blackett PR, Wilson DP, McNeal CJ. Secondary hypertriglyceridemia in children and adolescents. J Clin Lipidol 2015;9(5 Suppl):S29–S40
   Google Scholar
• Schmidt HH, Genschel J, Baier P, et al. Dyslipemia in familial partial lipodystrophy caused by an R482W mutation in the LMNA gene. J Clin Endocrinol Metab 2001;86:2289–95
   PubMed Web of Science ®Google Scholar
• Haque WA, Vuitch F, Garg A. Post-mortem findings in familial partial lipodystrophy, Dunnigan variety. Diabet Med 2002;19:1022–5
   PubMed Web of Science ®Google Scholar
• Herbst KL, Tannock LR, Deeb SS, et al. Kobberling type of familial partial lipodystrophy: an underrecognized syndrome. Diabetes Care 2003;26:1819–24
   PubMed Web of Science ®Google Scholar
• Francis GA, Li G, Casey R, et al. Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Med Genet 2006;7:3
   PubMed Web of Science ®Google Scholar
• Monajemi H, Stroes E, Hegele RA, et al. Inherited lipodystrophies and the metabolic syndrome. Clin Endocrinol (Oxf) 2007;67:479–84
   PubMed Web of Science ®Google Scholar
• Cao H, Alston L, Ruschman J, et al. Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia. Lipids Health Dis 2008;7:3
   PubMed Web of Science ®Google Scholar
• Madhra M, Noh RM, Zammitt NN, et al. A complicated pregnancy in a patient with lipodystrophic diabetes attributable to a peroxisome proliferator-activated receptor gamma (PPARG) mutation. Diabet Med 2012;29:e398–401
   PubMed Web of Science ®Google Scholar
• Islek A, Sayar E, Yilmaz A, et al. A very rare cause of acute pancreatitis: Berardinelli-Seip congenital lipodystrophy. Turk J Gastroenterol 2014;25(Suppl 1):216–19
   PubMed Web of Science ®Google Scholar
• Reue K, Brindley DN. Thematic review series: glycerolipids. Multiple roles for lipins/phosphatidate phosphatase enzymes in lipid metabolism. J Lipid Res 2008;49:2493–503
   PubMed Web of Science ®Google Scholar
• Bereziat V, Cervera P, Le Dour C, et al. LMNA mutations induce a non-inflammatory fibrosis and a brown fat-like dystrophy of enlarged cervical adipose tissue. Am J Pathol 2011;179:2443–53
   PubMed Web of Science ®Google Scholar
• Vatier C, Arnaud L, Prieur X, et al. One-year metreleptin therapy decreases PCSK9 serum levels in diabetic patients with monogenic lipodystrophy syndromes. Diabetes Metab 2017;43:275–9
   PubMed Web of Science ®Google Scholar